Lobbying & Influence

Work on Capitol Hill? Enjoy free access.

Biologics Battle Over Billions of Dollars

Fight Fueled by FTC Report That Says 12-Year Exclusivity Unnecessary

By Kate Ackley
Roll Call Staff
June 15, 2009, Midnight

Lobbyists who want Congress to approve a swift pathway to generic versions of biotech drugs say the Federal Trade Commission last week handed their side a boost just as Congress wades into the health care reform debate.

Obama’s Modification to Contraception Rule Mollifies Some, Not All 6 minutes ago
Bachus May Not Be Alone in Ethics Probe 41 minutes ago
Nine Things We've Learned at CPAC (So Far) 11:48 a.m.
Obama to Offer Birth Control Rule Compromise 11:16 a.m.
Cain Explains
Space Nazis Vs. Earth: What Would Gingrich Do?
Harry Reid to GOP: ‘Calm Down’ About Birth Control Rule

Slideshow |

February 9, 2012

Rep. Michele Bachmann, who recently suspended her campaign for the presidency, speaks at the 2012 Conservative Political Action Conference in Washington, D.C., on Feb. 9.

See More Multimedia

Email Newsletter Sign-Up

Breaking News Alerts
Morning and Afternoon Headlines
Heard on the Hill Updates

Follow Roll Call:

30 Hill Aides to Know

The clear expectation is Congress will get very little done this election year. But what does get accomplished, at least in the high-profile areas, will largely be the handiwork of an elite group of staffers — who combine policy expertise, political acumen and the trust of their lawmaker bosses to drive much of the legislative agenda.

Lobbying & Influence

Biologics Battle Over Billions of Dollars

Fight Fueled by FTC Report That Says 12-Year Exclusivity Unnecessary

Slideshow |

Email Newsletter Sign-Up

Follow Roll Call:

30 Hill Aides to Know

SIGN IN

SUBSCRIBE

Lobbying & Influence

Biologics Battle Over Billions of Dollars

Fight Fueled by FTC Report That Says 12-Year Exclusivity Unnecessary

More News

Slideshow |

Email Newsletter Sign-Up

Follow Roll Call:

30 Hill Aides to Know

SIGN IN

SUBSCRIBE